Citations

Showing 10 of 108152 citations.

Patient perceptions and use of non‐statin lipid lowering therapy among patients with or at risk for atherosclerotic cardiovascular disease: Insights from the PALM registry
Lowenstern, Angela , Li, Shuang , Návar, Ann Marie , Virani, Salim S. , Roger, Véronique L. , Robinson, Jennifer G. , Goldberg, Anne C. , Kampman, Wendy, Wang, Tracy Y., Navar, Ann Marie , Peterson, Eric D.

Mayo Clinic

Clinical Cardiology | May 19, 2021 | Volume: 44 | Issue: 6 | Pages: 863-870

10.1002/clc.23625 | PMID 34008247 Get It

AbstractBackgroundNon‐statin lipid lowering therapies (LLTs) provide additional treatment options for patients. Use patterns and patient perceptions of non‐statin LLT remain incompletely described.HypothesisThe guideline‐recommended statin intensity remains underutilized in patients treated with and without non‐statin LLT.MethodsThe PALM Registry collected LLT information on patients with or at risk of ASCVD treated at 125 US clinics in 2015. We compared patient perceptions, lipid levels and statin use among patients treated with and without non‐statin LLT.ResultsAmong 7720 patients, 1930 (25.0%) were treated with a non‐statin LLT (1249 fish oil, 417 fibrates, 329 ezetimibe, 196 niacin). Concurrent statin treatment occurred in 73.7%, of which 45.4% were dosed under the guideline‐recommended intensity. Compared with patients on statin alone, patients receiving both a statin and non‐statin LLT (n = 1423) were more likely to be male, white race and to perceive themselves as higher risk of ASCVD compared with their peers (38.5% vs. 34.9%, p = .047). Only 27.4% of patients treated with non‐statin LLT alone perceived themselves at higher risk. Most (75.7%) patients treated with a non‐statin LLT alone reported never being treated with a statin, despite ASCVD in 30.8% of these patients. Among those previously treated with a statin, 59.3% reported being willing to try a statin again.ConclusionsNon‐statin LLT is used in one in four patients with or at risk for ASCVD; its use is frequently in place of statin therapy or in the absence of guideline‐recommended statin intensity. More work is needed to establish statins as first line therapy.
Recurrence of Primary Sclerosing Cholangitis After Liver Transplant in Children: An International Observational Study
Martínez, Mercedes , Perito, Emily R. , Valentino, Pamela L. , Mack, Cara L. , Aumar, Madeleine , Broderick, Annemarie , Draijer, Laura G. , Furuya, Katryn N. , Gupta, Nitika , Horslen, Simon , Jonas, Maureen M. , Kamath, Binita M. , Kerkar, Nanda , Kolho, Kaija‐Leena , Koot, Bart G.P. , Laborda, Trevor J., Loomes, Kathleen M. , Miloh, Tamir , Mogul, Douglas , Mohammed, Saeed, Ovchinsky, Nadia , Rao, Girish S. , Ricciuto, Amanda , Ferreira, Alexandre Rodrígues , Schwarz, Kathleen B. , Smolka, Vratislav, Tessier, Mary Elizabeth M. , Venkat, Venna L., Vitola, Bernadette , Woynarowski, Marek , Zerofsky, Melissa , Valentino, Pamela , Mohammad, Saeed , Ovchinsky, Nadia , Ricciuto, Amanda , Deneau, Mark R , Martinez, Mercedes , Fagundes, Eleonora Druve Tavares , Kim, Kyung Mo , Lee, Christine Kyuyoung , Tanaka, Atsushi , Deneau, Mark

Mayo Clinic

Hepatology | May 19, 2021 | Volume: 74 | Issue: 4 | Pages: 2047-2057

10.1002/hep.31911 | PMID 34008252 Get It

Background and Aims Recurrent primary sclerosing cholangitis (rPSC) following liver transplant (LT) has a negative impact on graft and patient survival; little is known about risk factors for rPSC or disease course in children. Approach and Results We retrospectively evaluated risk factors for rPSC in 140 children from the Pediatric PSC Consortium, a multicenter international registry. Recipients underwent LT for PSC and had >90 days of follow‐up. The primary outcome, rPSC, was defined using Graziadei criteria. Median follow‐up after LT was 3 years (interquartile range 1.1‐6.1). rPSC occurred in 36 children, representing 10% and 27% of the subjects at 2 years and 5 years following LT, respectively. Subjects with rPSC were younger at LT (12.9 vs. 16.2 years), had faster progression from PSC diagnosis to LT (2.5 vs. 4.1 years), and had higher alanine aminotransferase (112 vs. 66 IU/L) at LT (all P < 0.01). Inflammatory bowel disease was more prevalent in the rPSC group (86% vs. 66%; P = 0.025). After LT, rPSC subjects had more episodes of biopsy‐proved acute rejection (mean 3 vs. 1; P < 0.001), and higher prevalence of steroid‐refractory rejection (41% vs. 20%; P = 0.04). In those with rPSC, 43% developed complications of portal hypertension, were relisted for LT, or died within 2 years of the diagnosis. Mortality was higher in the rPSC group (11.1% vs. 2.9%; P = 0.05). Conclusions The incidence of rPSC in this cohort was higher than previously reported, and was associated with increased morbidity and mortality. Patients with rPSC appeared to have a more aggressive, immune‐reactive phenotype. These findings underscore the need to understand the immune mechanisms of rPSC, to lay the foundation for developing new therapies and improve outcomes in this challenging population.
The Role of Surgical Lung Biopsy in the Diagnosis of Fibrotic Interstitial Lung Disease: Perspective from the Pulmonary Fibrosis Foundation
Roden, Anja C. , Manjarres, D.C. Gomez, Hartwig, Matthew G. , Kheir, Fayez , King, Christopher S. , Kreider, Maryl , Lynch, David A. , Mooney, Joshua J. , Muniappan, Ashok , Paoletti, Luca , Raj, Rishi , Suliman, Sally , Thavarajah, Krishna, Rudell, Frederick L., Bianchi, Pauline , Shea, Barry S. , Ley, Brett, Kheir, Fayez , Mooney, Joshua , Lederer, David J , Hariri, Lida P. , Chung, Jonathan Hero , Danoff, Sonye Karen , Myers, Jeffrey L. , Safdar, Zeenat , Lederer, David J.

Mayo Clinic

Annals of the American Thoracic Society | May 18, 2021 | Volume: 18 | Issue: 10 | Pages: 1601-1609

10.1513/annalsats.202009-1179fr | PMID 34004127 Get It

Abstract Diagnosis of interstitial lung disease (ILD) requires a multidisciplinary discussion approach that includes clinicians, radiologists, and pathologists. Surgical lung biopsy (SLB) is currently the recommended standard in obtaining pathologic specimens for patients with ILD requiring a tissue diagnosis. The increased diagnostic confidence and accuracy provided by microscopic pathology assessment of SLB specimens must be balanced with the associated risks in patients with ILD. This document was developed by the SLB Working Group of the Pulmonary Fibrosis Foundation, composed of a multidisciplinary group of ILD physicians, including pulmonologists, radiologists, pathologists, and thoracic surgeons. In this document, we present an up-to-date literature review of the indications, contraindications, risks, and alternatives to SLB in the diagnosis of fibrotic ILD; outline an integrated approach to the decision-making around SLB in the diagnosis of fibrotic ILD; and provide practical information to maximize the yield and safety of SLB.
Radiotherapy and Receptor Tyrosine Kinase Inhibition for Solid Cancers (ROCKIT): A Meta-Analysis of 13 Studies
Tchelebi, Leila T. , Batchelder, Emma , Wang, Ming , Lehrer, Eric J. , Drabick, Joseph J. , Sharma, Navesh , Machtay, Mitchell , Trifiletti, Daniel M. , Zaorsky, Nicholas G , Trifiletti, Daniel M , Tchelebi, Leila , Wang, Ming , Zaorsky, Nicholas G.

Mayo Clinic

JNCI Cancer Spectrum | May 18, 2021 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/jncics/pkab050 | PMID 34350378 Get It

Abstract Background We hypothesized that the addition of receptor tyrosine kinase inhibitors (RTKis, e.g., lapatinib, erlotinib, cetuximab, bevacizumab, panitumumab) to radiotherapy-based treatment for solid tumors does not increase overall survival but may increase toxicity. Methods Population, Intervention, Control, Outcome, Study Design; Preferred Reporting Items for Systematic Reviews and Meta-Analyses; and Meta-analysis of Observational Studies in Epidemiology methods were used to identify prospective randomized studies including patients with solid tumor cancers treated with radiotherapy with or without RTKis. Extracted variables included use of radiotherapy vs chemoradiotherapy, RTKi type (antibody vs small molecule), outcomes, and toxicities. The primary endpoint was overall survival; the secondary endpoint was grade 3+ toxicity. Random-effects meta-analyses were performed for each outcome measure. All statistical tests were 2-sided. Results A total of 405 studies met the initial search criteria, of which 13 prospective randomized trials of radiotherapy with or without RTKi met the inclusion criteria, encompassing 5678 patients. The trials included cancers of the head and neck (6 trials, 3295 patients), esophagus (3 trials, 762 patients), lung (2 trials, 550 patients), and brain (2 trials, 1542 patients). Three studies evaluated a small molecule and radiotherapy in 949 patients, and 10 studies evaluated antibodies and radiotherapy in 4729 patients. The addition of RTKis to radiotherapy-based treatment did not improve overall survival (hazard ratio = 1.02, 95% confidence interval = 0.90 to 1.15, P = .76) but increased grade 3+ toxicity (relative risk = 1.18, 95% confidence interval = 1.06 to 1.33, P = .009). Conclusions The addition of RTKis to radiotherapy does not improve survival and worsens toxicity.
Expression of ACE2 in the Intact and Acutely Injured Kidney
Nath, Karl A. , Singh, Raman Deep , Grande, Joseph P. , Croatt, Anthony J., Ackerman, Allan W., Barry, Michael A. , Barry, Michael A , Garovic, Vesna D. , Agarwal, Anupam

Mayo Clinic

Kidney360 | May 18, 2021 | Volume: 2 | Issue: 7 | Pages: 1095-1106

10.34067/kid.0001562021 | PMID 35368365 Get It

Abstract Key Points The healthy kidney prominently expresses angiotensin-converting enzyme 2 (ACE2) mRNA, protein, and activity, with ACE2 protein abundantly displayed in proximal tubules. Renal ACE2 expression decreases after ischemic AKI but is induced by LPS in a heme oxygenase-1-dependent manner. ACE2 induction/angiotensin (1–7) and angiotensin (1–7) may offer therapeutic approaches for AKI without or with coronavirus disease 2019, respectively. Background The actions of angiotensin-converting enzyme 2 (ACE2) oppose those of the renin-angiotensin-aldosterone system. ACE2 may be a cytoprotectant in some tissues. This study examined ACE2 expression in models of AKI. Methods ACE2 mRNA and protein expression and ACE2 activity were assessed in murine ischemic AKI. Renal ACE2 mRNA expression was evaluated in LPS-induced AKI in wild-type (C57BL/6J) mice, in heme oxygenase-1 +/+ and heme oxygenase-1 −/− mice, and after unilateral ureteral obstruction (UUO) in wild-type mice. The effect of sex and age on renal ACE2 protein expression was also assessed. Results In ischemic AKI, ACE2 mRNA and protein expression and ACE2 activity were reduced as compared with such indices in the intact kidney. In ischemic AKI, ACE2, which, in health, is prominently expressed in the tubular epithelium, especially proximal tubules, is decreased in expression in these segments. Decreased ACE2 expression in AKI did not reflect reduced GFR, because ACE2 mRNA expression was unaltered after UUO. LPS induced renal ACE2 mRNA expression in wild-type mice, but this effect did not occur in heme oxygenase-1–deficient mice. In ischemic and LPS-induced AKI, renal expression of the Mas receptor was increased. In the intact kidney, renal ACE2 protein expression decreased in female mice as compared with male mice, but was unaltered with age. Conclusion We conclude that renal ACE2 expression is decreased in ischemic AKI, characterized by decreased GFR and abundant cell death, but is upregulated in LPS-induced AKI, an effect requiring heme oxygenase-1. Determining the significance of ACE2 expression in experimental AKI merits further study. We suggest that understanding the mechanism underlying ACE2 downregulation in AKI may offer insights relevant to COVID-19: ACE2 expression is downregulated after ACE2 mediates SARS-CoV-2 cellular entry; such downregulation is proinflammatory; and AKI commonly occurs and determines outcomes in COVID-19.
Rhabdomyosarcoma with epithelioid morphology: A challenging cytologic diagnosis in a pleural effusion
Rodgers, Shannon , Datta, Lagnajita, Perry, Kyle , Stone, Chad H.

Mayo Clinic

Diagnostic Cytopathology | May 18, 2021 | Volume: 49 | Issue: 9 | Pages: No page available

10.1002/dc.24803 | PMID 34004052 Get It

AbstractRhabdomyosarcomas (RMS) are rare malignant skeletal muscle tumors that present more commonly in pediatric populations. The WHO currently classifies RMS into four types, embryonal, alveolar, pleomorphic, and spindle cell/sclerosing variants. Epithelioid rhabdomyosarcoma (EpiRMS) is another rare, recently described subtype of RMS presenting in older patients with a male predominance and has a rapidly progressive clinical course with frequent metastases. EpiRMS closely mimics poorly differentiated carcinoma or melanoma, demonstrating discohesive large epithelioid cells with abundant eosinophilic cytoplasm, frequent glassy cytoplasmic inclusions, large vesicular nuclei, and prominent nucleoli. We present a case of metastatic rhabdomyosarcoma with features reminiscent of EpiRMS presenting as a pleural effusion, closely followed by an inguinal lymph node biopsy. The malignant cells in the pleural fluid were diffusely positive for desmin, negative for MyoD1, myogenin, S100 and SOX10, and retained INI‐1 expression. Subsequent lymph node biopsy demonstrated identical malignant epithelioid cells that were positive for desmin, myoD1 and myogenin, and a cytological diagnosis of “metastatic rhabdomyosarcoma, favor epithelioid rhabdomyosarcoma” was given considering the concurrent lymph node biopsy morphology and immunoprofile. A diagnosis of rhabdomyosarcoma, though rare and challenging, should not be overlooked when considering malignant cells with an epithelioid morphology in cytology specimens.
Development of a Patient-Specific p.D85N-Potassium Voltage-Gated Channel Subfamily E Member 1–Induced Pluripotent Stem Cell–Derived Cardiomyocyte Model for Drug-Induced Long QT Syndrome
Ye, Dan , Kim, C.S. John, Zhou, Wei , Tester, David J. , Giudicessi, John R. , Ackerman, Michael J. , Kim, Maengjo , Ye, Dan

Mayo Clinic

Circulation: Genomic and Precision Medicine | May 18, 2021 | Volume: 14 | Issue: 3 | Pages: No page available

10.1161/circgen.120.003234 | PMID 34003017 Get It

Background: Prior epidemiological studies demonstrated that the p.D85N-Potassium voltage-gated channel subfamily E member 1 (KCNE1) common variant reduces repolarization reserve and predisposes to drug-induced QT prolongation/torsades de pointes. We sought to develop a cellular model for drug-induced long QT syndrome using a patient-specific induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM). Methods: p.D85N-KCNE1 iPSCs were generated from a 23-year-old female with an exaggerated heart rate-corrected QT interval response to metoclopramide (ΔQTc of 160 ms). Clustered regularly interspaced short palindromic repeats-associated 9 technology was used to generate gene-corrected isogenic iPSCs. Field potential duration and action potential duration (APD) were measured from iPSC-CMs. Results: At baseline, p.D85N-KCNE1 iPSC-CMs displayed significantly longer field potential duration (281±15 ms, n=13 versus 223±8.6 ms, n=14, P <0.01) and action potential duration at 90% repolarization (APD90; 579±22 ms, n=24 versus 465±33 ms, n=26, P <0.01) than isogenic-control iPSC-CMs. Dofetilide at a concentration of 2 nM increased significantly field potential duration (379±20 ms, n=13, P <0.01) and APD90 (666±11 ms, n=46, P <0.01) in p.D85N-KCNE1 iPSC-CMs but not in isogenic-control. The effect of dofetilide on APD90 (616±54 ms, n=7 versus 526±54 ms, n=10, P <0.05) was confirmed by Patch-clamp. Interestingly, treatment of p.D85N-KCNE1 iPSC-CMs with estrogen at a concentration of 1 nM exaggerated further dofetilide-induced APD90 prolongation (696±9 ms, n=81, P <0.01) and caused more early afterdepolarizations (11.7%) compared with isogenic control (APD90: 618±8 ms, n=115 and early afterdepolarizations: 2.6%, P <0.05). Conclusions: This iPSC-CM study provides further evidence that the p.D85N-KCNE1 common variant in combination with environmental factors such as QT prolonging drugs and female sex is proarrhythmic.
Secondary cytogenetic abnormalities in core-binding factor AML harboring inv(16) vs t(8;21)
Han, Se young, Mrózek, Krzysztof , Morgan, Elizabeth A. , Vestergaard, Hanne , Ohgami, Robert S. , Kluin, Philip M., Kristensen, Thomas Kielsgaard , Pullarkat, Sheeja T. , Møller, Michael , Kim, Young , Czuchlewski, David R., Hilberink, Jacobien R. , Horny, Hans-Peter, Dolan, Michelle, Ku, Nam K., Yi, Cecilia Arana , Pullarkat, Vinod , Kohlschmidt, Jessica, Salhotra, Amandeep , Soma, Lori , Bloomfield, Clara D. , Chen, Dong , Sperr, Wolfgang R. , Marcucci, Guido , Cho, Christina , Broesby‐Olsen, Sigurd , Larson, Melissa L., Deeg, H. Joachim , Hoermann, Gregor , Litzow, Mark R. , Nakamura, Ryotaro , Weisdorf, Daniel J. , Huls, Gerwin , Valent, Peter , Üstün, Celalettin , Morgan, Elizabeth A , Vestergaard, Hanne , Møller, Michael Boe , Schiefer, Ana-Iris , Hilberink, Jacobien R , Arana Yi, Cecilia , Deeg, H Joachim , Perales, Miguel-Angel , Litzow, Mark R. , Nakamura, Ryotaro , Weisdorf, Dan , Valent, Peter , Ustun, Celalettin , Yeung, Cecilia , Chen, Dong , Sperr, Wolfgang , Voutsinas, Jenna M. , Wu, Qian Vicky , Baughn, Linda B. , George, Tracy I. , Akin, Cem , Gotlib, Jason , Linden, Michael A. , Perales, Miguel‐Angel , Hornick, Jason L. , Borthakur, Gautam , Yeung, Cecilia C.S.

Mayo Clinic

Blood Advances | May 18, 2021 | Volume: 5 | Issue: 10 | Pages: 2481-2489

10.1182/bloodadvances.2020003605 | PMID 34003250 Get It

Abstract Patients with core-binding factor (CBF) acute myeloid leukemia (AML), caused by either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22), have higher complete remission rates and longer survival than patients with other subtypes of AML. However, ∼40% of patients relapse, and the literature suggests that patients with inv(16) fare differently from those with t(8;21). We retrospectively analyzed 537 patients with CBF-AML, focusing on additional cytogenetic aberrations to examine their impact on clinical outcomes. Trisomies of chromosomes 8, 21, or 22 were significantly more common in patients with inv(16)/t(16;16): 16% vs 7%, 6% vs 0%, and 17% vs 0%, respectively. In contrast, del(9q) and loss of a sex chromosome were more frequent in patients with t(8;21): 15% vs 0.4% for del(9q), 37% vs 0% for loss of X in females, and 44% vs 5% for loss of Y in males. Hyperdiploidy was more frequent in patients with inv(16) (25% vs 9%, whereas hypodiploidy was more frequent in patients with t(8;21) (37% vs 3%. In multivariable analyses (adjusted for age, white blood counts at diagnosis, and KIT mutation status), trisomy 8 was associated with improved overall survival (OS) in inv(16), whereas the presence of other chromosomal abnormalities (not trisomy 8) was associated with decreased OS. In patients with t(8;21), hypodiploidy was associated with improved disease-free survival; hyperdiploidy and del(9q) were associated with improved OS. KIT mutation (either positive or not tested, compared with negative) conferred poor prognoses in univariate analysis only in patients with t(8;21).
Diffusion models reveal white matter microstructural changes with ageing, pathology and cognition
Raghavan, Sheelakumari , Przybelski, Scott A. , Lesnick, Timothy G. , Graff‐Radford, Jonathan , Mielke, Michelle M. , Petersen, Ronald C. , Jack, Clifford R. , Vemuri, Prashanthi , Graff-Radford, Jonathan , Mielke, Michelle M , Vemuri, Prashanthi , Jack, Clifford R , Reid, Robert I. , Schwarz, Christopher G. , Knopman, David S. , Machulda, Mary M.

Mayo Clinic

Brain Communications | May 18, 2021 | Volume: 3 | Issue: 2 | Pages: No page available

10.1093/braincomms/fcab106 | PMID 34136811 Get It

Abstract White matter microstructure undergoes progressive changes during the lifespan, but the neurobiological underpinnings related to ageing and disease remains unclear. We used an advanced diffusion MRI, Neurite Orientation Dispersion and Density Imaging, to investigate the microstructural alterations due to demographics, common age-related pathological processes (amyloid, tau and white matter hyperintensities) and cognition. We also compared Neurite Orientation Dispersion and Density Imaging findings to the older Diffusion Tensor Imaging model-based findings. Three hundred and twenty-eight participants (264 cognitively unimpaired, 57 mild cognitive impairment and 7 dementia with a mean age of 68.3 ± 13.1 years) from the Mayo Clinic Study of Aging with multi-shell diffusion imaging, fluid attenuated inversion recovery MRI as well as amyloid and tau PET scans were included in this study. White matter tract level diffusion measures were calculated from Diffusion Tensor Imaging and Neurite Orientation Dispersion and Density Imaging. Pearson correlation and multiple linear regression analyses were performed with diffusion measures as the outcome and age, sex, education/occupation, white matter hyperintensities, amyloid and tau as predictors. Analyses were also performed with each diffusion MRI measure as a predictor of cognitive outcomes. Age and white matter hyperintensities were the strongest predictors of all white matter diffusion measures with low associations with amyloid and tau. However, neurite density decrease from Neurite Orientation Dispersion and Density Imaging was observed with amyloidosis specifically in the temporal lobes. White matter integrity (mean diffusivity and free water) in the corpus callosum showed the greatest associations with cognitive measures. All diffusion measures provided information about white matter ageing and white matter changes due to age-related pathological processes and were associated with cognition. Neurite orientation dispersion and density imaging and diffusion tensor imaging are two different diffusion models that provide distinct information about variation in white matter microstructural integrity. Neurite Orientation Dispersion and Density Imaging provides additional information about synaptic density, organization and free water content which may aid in providing mechanistic insights into disease progression.